Results from a phase I/II trial of cusatuzumab combined with azacitidine in patients with newly diagnosed acute myeloid leukemia who are ineligible for intensive chemotherapy

Cusatuzumab is a high-affinity, anti-CD70 monoclonal antibody under investigation in acute myeloid leukemia (AML). This two-part, open-label, multicenter, phase I/II trial evaluated cusatuzumab plus azacitidine in patients with newly diagnosed AML ineligible for intensive chemotherapy. Patients rece...

Descripción completa

Detalles Bibliográficos
Autores principales: Pabst, Thomas, Vey, Norbert, Adès, Lionel, Bacher, Ulrike, Bargetzi, Mario, Fung, Samson, Gaidano, Gianluca, Gandini, Domenica, Hultberg, Anna, Johnson, Amy, Ma, Xuewen, Müller, Rouven, Nottage, Kerri, Papayannidis, Cristina, Recher, Christian, Riether, Carsten, Shah, Priya, Tryon, Jeffrey, Xiu, Liang, Ochsenbein, Adrian F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Fondazione Ferrata Storti 2023
Materias:
Article - Acute Myeloid Leukemia
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10316251/
https://www.ncbi.nlm.nih.gov/pubmed/36779592
http://dx.doi.org/10.3324/haematol.2022.281563

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10316251/
https://www.ncbi.nlm.nih.gov/pubmed/36779592
http://dx.doi.org/10.3324/haematol.2022.281563

Ejemplares similares